Open Access

A novel mechanism for the anticancer activity of aspirin and salicylates

  • Authors:
    • Asma'u I.J. Bashir
    • Chandra S. Kankipati
    • Sarah Jones
    • Robert M. Newman
    • Stephen T. Safrany
    • Christopher J. Perry
    • Iain D. Nicholl
  • View Affiliations

  • Published online on: January 29, 2019     https://doi.org/10.3892/ijo.2019.4701
  • Pages: 1256-1270
  • Copyright: © Bashir et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Epidemiological studies indicate that long‑term aspirin usage reduces the incidence of colorectal cancer (CRC) and may protect against other non‑CRC associated adenocarcinomas, including oesophageal cancer. A number of hypotheses have been proposed with respect to the molecular action of aspirin and other non‑steroidal anti‑inflammatory drugs in cancer development. The mechanism by which aspirin exhibits toxicity to CRC has been previously investigated by synthesising novel analogues and derivatives of aspirin in an effort to identify functionally significant moieties. Herein, an early effect of aspirin and aspirin‑like analogues against the SW480 CRC cell line was investigated, with a particular focus on critical molecules in the epidermal growth factor (EGF) pathway. The present authors proposed that aspirin, diaspirin and analogues, and diflunisal (a salicylic acid derivative) may rapidly perturb EGF and EGF receptor (EGFR) internalisation. Upon longer incubations, the diaspirins and thioaspirins may inhibit EGFR phosphorylation at Tyr1045 and Tyr1173. It was additionally demonstrated, using a qualitative approach, that EGF internalisation in the SW480 cell line may be directed to endosomes by fumaryldiaspirin using early endosome antigen 1 as an early endosomal marker and that EGF internalisation may also be perturbed in oesophageal cell lines, suggestive of an effect not only restricted to CRC cells. Taken together and in light of our previous findings that the aspirin‑like analogues can affect cyclin D1 expression and nuclear factor‑κB localisation, it was hypothesized that aspirin and aspirin analogues significantly and swiftly perturb the EGFR axis and that the protective activity of aspirin may in part be explained by perturbed EGFR internalisation and activation. These findings may also have implications in understanding the inhibitory effect of aspirin and salicylates on wound healing, given the critical role of EGF in the response to tissue trauma.
View Figures
View References

Related Articles

Journal Cover

April 2019
Volume 54 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Bashir, A.I., Kankipati, C.S., Jones, S., Newman, R.M., Safrany, S.T., Perry, C.J., & Nicholl, I.D. (2019). A novel mechanism for the anticancer activity of aspirin and salicylates. International Journal of Oncology, 54, 1256-1270. https://doi.org/10.3892/ijo.2019.4701
MLA
Bashir, A. I., Kankipati, C. S., Jones, S., Newman, R. M., Safrany, S. T., Perry, C. J., Nicholl, I. D."A novel mechanism for the anticancer activity of aspirin and salicylates". International Journal of Oncology 54.4 (2019): 1256-1270.
Chicago
Bashir, A. I., Kankipati, C. S., Jones, S., Newman, R. M., Safrany, S. T., Perry, C. J., Nicholl, I. D."A novel mechanism for the anticancer activity of aspirin and salicylates". International Journal of Oncology 54, no. 4 (2019): 1256-1270. https://doi.org/10.3892/ijo.2019.4701